{"entity":{"id":"paper-scott-tnbc-disparities-uscs-cancer-2019","kind":"paper","name":"Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014","aka":[],"tldr":"A count of 1.15 million US breast cancers from 2010 to 2014 in which Black women had 2.27 times the odds of a triple-negative diagnosis and women under 40 nearly twice the odds, confirming the disparity at national scale.","summary":"Scott, Mobley, Kuo and Il'yasova examined differences between triple-negative and other breast cancers by age, race and ethnicity and stage in the United States Cancer Statistics database. Of 1,151,724 breast cancers identified from 2010 through 2014, the triple-negative phenotype accounted for about 8.4 percent. In unadjusted analyses non-Hispanic Black women (odds ratio 2.27, 95 percent confidence interval 2.23 to 2.31) and Hispanic women (1.22, 1.19 to 1.25) had higher odds of a triple-negative diagnosis than non-Hispanic white women; women under 40 had the highest odds compared with women aged 50 to 64 (1.95, 1.90 to 2.01); stage III (1.69) and stage IV (1.47) at diagnosis conferred higher odds. Results varied slightly after adjustment.","asOf":"2026-09-24","links":[{"label":"Cancer 2019","url":"https://doi.org/10.1002/cncr.32207"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31282032/"}],"tags":["tnbc-evidence"],"related":["paper-howlader-us-incidence-breast-subtypes-jnci-2014","paper-bauer-triple-negative-california-registry-cancer-2007"],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-trial-diversity","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Cancer","year":2019,"doi":"10.1002/cncr.32207","pmid":"31282032","authors":"Scott LC, Mobley LR, Kuo TM, et al.","paperType":"observational","findings":["Triple-negative phenotype in about 8.4 percent of 1,151,724 US breast cancers, 2010 to 2014.","Odds of triple-negative diagnosis: non-Hispanic Black 2.27 (95 percent CI 2.23 to 2.31); Hispanic 1.22; age under 40 1.95; stage III 1.69; stage IV 1.47."],"whatItMeans":"The most recent national figure behind the statement that Black women in the United States have about twice the incidence of triple-negative breast cancer; trial enrolment has not matched it.","caveats":["Unadjusted odds ratios are the headline figures; adjusted results differed slightly.","The 8.4 percent share is lower than SEER's 12.2 percent, reflecting unknown-status coding across registries."],"changedPractice":false,"participants":1151724},"route":"/key-papers/paper-scott-tnbc-disparities-uscs-cancer-2019/","neighbours":{"paper":[{"id":"paper-bauer-triple-negative-california-registry-cancer-2007","kind":"paper","name":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry","route":"/key-papers/paper-bauer-triple-negative-california-registry-cancer-2007/"},{"id":"paper-howlader-us-incidence-breast-subtypes-jnci-2014","kind":"paper","name":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","route":"/key-papers/paper-howlader-us-incidence-breast-subtypes-jnci-2014/"}],"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"idea":[{"id":"idea-tnbc-disparities-in-access-and-outcomes","kind":"idea","name":"Close the gap between who gets triple-negative breast cancer and who is in its trials","route":"/ideas/idea-tnbc-disparities-in-access-and-outcomes/"},{"id":"idea-tnbc-uk-ethnicity-stratified-outcome-reporting","kind":"idea","name":"Ethnicity-stratified outcome reporting for triple-negative breast cancer in NHS cancer statistics","route":"/ideas/idea-tnbc-uk-ethnicity-stratified-outcome-reporting/"}]}}